發送短信 : Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

   _____    ______              _____     _  __  
  / ___//  /_   _//     ___    |  ___||  | |/ // 
  \___ \\   -| ||-     /   ||  | ||__    | ' //  
  /    //   _| ||_    | [] ||  | ||__    | . \\  
 /____//   /_____//    \__ ||  |_____||  |_|\_\\ 
`-----`    `-----`      -|_||  `-----`   `-` --` 
                         `-`